TG Therapeutics reports development for Umbralisib
TG Therapeutics Inc. (TGTX) reported that the FDA has accepted its New Drug Application for umbralisib. The drug candidate will be reviewed under the Priority Review pathway. It had been granted Breakthrough Therapy tag for treating marginal zone lymphoma condition. Its Prescription Drug User Fee Act (PDUFA) goal date has been set at February 15, 2021. For follicular lymphoma, the drug candidate will undergo standard review and the PDUFA goal date of June 15, 2021, has been set.
TG Therapeutics has used data from the umbralisib monotherapy MZL and FL cohorts of the UNITY-NHL Phase 2b trial for supporting its NDA. The trial was set to assess the potential of umbralisib in treating patients suffering from marginal zone lymphoma or follicular lymphoma. Michael S. Weiss of TG Therapeutics said:
If approved, we believe umbralisib could become an important treatment option for patients with previously treated MZL and FL. We look forward to presenting the data from the UNITY-NHL trial that supported this NDA submission by year end."
TG Therapeutics had earlier reported that each cohort of the trial had met its primary endpoint pertaining overall response rate. The company's target guidance was pegged at 40 to 50 percent ORR and its achievement was confirmed by an Independent Review Committee. The drug candidate was tagged as an orphan drug for both the indications of MZL and FL.
The UNITY-NHL trial is a global multicenter, open-label Phase 2b trial. Its MZL cohort aimed to assess the safety and efficacy of single-agent umbralisib in patients with MZL who have been administered at least one prior anti-CD20 regimen. All treated MZL patients met the primary endpoint of overall response rate.
The follicular Lymphoma cohort aimed to assess the safety and efficacy of single-agent umbralisib in patients with FL who were relapsed or refractory following at least two prior lines of therapy, including an anti-CD20 regimen and an alkylating agent. All treated FL patients also met the primary endpoint of ORR. The results were also in line with the company's pre-decided response target of 40 to 50 percent ORR.
On June 15, 2020, TG Therapeutics reported that it has completed the rolling submission of an NDA to the FDA. The company had requested the FDA for accelerated approval of the drug candidate for treating patients with previously treated MZL and FL. The company's request has now been accepted by the FDA.
TG Therapeutics is mainly invested in acquiring, developing, and commercializing treatments for various autoimmune diseases and B-cell malignancies. The company currently has two investigational compounds in late-stage clinical development phase. These two compounds are ublituximab and umbralisib and they target autoimmune ailments and hematological malignancies.
Ublituximab is a glycoengineered monoclonal antibody and works by targeting a particular epitope on the CD20 antigen found on mature B-lymphocytes. Umbralisib is an oral dual inhibitor and is designed to be taken once a day daily. TG Therapeutics has a robust development pipeline with two fully enrolled identical Phase 3 trials evaluating ublituximab monotherapy in patients with relapsing forms of multiple sclerosis.
Mesoblast Limited (MESO) announced that the Oncologic Drugs Advisory Committee of the FDA has voted in favor of Ryoncil in pediatric patients with steroid-refractory acute graft versus host disease. The ODAC is an independent panel of experts that assesses the efficacy and safety of data for the purpose of making appropriate recommendations to the FDA.
The news has come as a surprise to many industry experts as the company had been marred with several issues pertaining to the drug candidate. It has been noted that the review team had raised concerns regarding the data presented by the company with its application. The committee had raised concerns that the main pediatric study, MSB-GVHD001, allowed the use of other agents, which might have compromised the outcomes.
While the FDA takes committee recommendation into account while delivering the final verdict, it has no obligation to follow such recommendation. Dr. Fred Grossman of Mesoblast said:
We are very encouraged by today's outcome and are committed to working closely with the FDA as they complete their review of our submission regarding approval of RYONCIL for this life-threatening complication of an allogeneic bone marrow transplant."
The drug candidate has been given an action date of September 30, 2020, under the Prescription Drug User Fee Act.
Ryoncil is the lead drug candidate for Mesoblast. It is an investigational therapy comprising culture-expanded mesenchymal stem cells. These cells are taken from the bone marrow of an unrelated donor. The drug candidate is deemed to have immunomodulatory properties for counteracting the inflammatory processes. These processes may down regulate the production of pro-inflammatory cytokines and thus may expand the production of anti-inflammatory cytokines and allowing recruitment of naturally occurring anti-inflammatory cells to involved tissues.
Imara Inc. (IMRA) announced the dosing of the first patient for the company's Ardent Phase 2b clinical trial of IMR-687 for adult patients with sickle cell disease. The company had earlier reported the data from the second planned interim analysis of Phase 2a clinical trial of IMR-687. The company is looking to report top-line data from this Phase 2a clinical trial in the fourth quarter of 2020.
IMR-687 Phase 2b Clinical Trial is a global, randomized, double-blind, placebo-controlled, multicenter study under the name of Ardent. The study will have nearly 99 adult patients suffering from sickle cell disease and will be randomized using hydroxyurea and the region. Doses will be based on weight to optimize tolerability and drug exposure.
The primary efficacy objective of the trial is to assess the proportion of all patients with fetal hemoglobin (HbF) response. The endpoint has been defined as an increase of 3% in HbF from baseline to week 24, compared to placebo. Rahul Ballal, CEO of Imara said:
Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687."
During the trial, the patients will be kept on treatment through 52 weeks to gather data for planned secondary and additional exploratory endpoints. Some of these endpoints are indices of red cell hemolysis, quality of life measures, and HbF-associated biomarkers. Once the period of 52 weeks of treatment is over, patients will be entitled to be enrolled in an open-label extension study.
IMR-687 is a highly selective and potent small-molecule inhibitor of PDE9. People suffering from SCD and beta-thalassemia generally have lower levels of cGMP and may experience greater cell adhesion and reduced blood flow in addition to the decline in nitric oxide-mediated vasodilation.
Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.
That means that when the catalyst comes that will make or break a stock, we've positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
See the rest here:
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments